72 results about "Hippocampal neuron" patented technology

The invention belongs to the field of traditional Chinese medicines, and particularly discloses a traditional Chinese medicine composition with an anti-depression effect, which is prepared from the following medicinal materials by weight: 6g of pericarpium citri reticulatae viride, 6g of pericarpium citri reticulatae, 6g of radix paeoniae alba, 6g of thunberg fritillary bulb, 4.5 g of rhizoma alismatis, 4.5 g of fried gardenia and 4.5 g of moutan bark. The composition regulates functions of hypothalamus-pituitary-adrenal axis (HPA axis) and repairs hippocampal neurons and relieves symptoms such as pleasant sensation loss and behavioral despair of depression patients by relieving qi stagnation, clearing heat, cooling blood, promoting diuresis and reducing phlegm. Experiments prove that the traditional Chinese medicine composition can remarkably improve the sweet water preference rate of depression rats, shorten the forced swimming immobility time, reduce the levels of CRH, ACTH and CORT of plasma and improve pathological injuries of hippocampus tissues. The composition adopts medicinal and edible medicinal materials, is small in side effect and high in safety, and can be prepared into an oral preparation for treating depression.

The invention discloses application of lactobacillus muricatum in preparation of a medicine for preventing and / or treating depression in the technical field of microorganisms, and the lactobacillus muricatum is preserved in the China Industrial Microbiological Culture Collection Center (CICC) with the preservation number of CICC23140. Research finds that lactobacillus muricatum which is preserved in the China Industrial Microbiological Culture Collection Center and has the preservation number of CICC23140 has a good effect of improving and / or preventing and / or treating cortisol-induced depression, and inactivated lactobacillus muricatum can effectively prevent hippocampal neuron damage, reduce expression of inflammatory factors in the brain, prevent and treat cortisol-induced depression, and can be used for preventing and treating cortisol-induced depression. Not only can the anxiety symptom of depression be improved, but also dyskinesia can be relieved.

The invention discloses construction and application of a Primrose syndrome non-human animal model, and belongs to the technical field of animal models and disease research. According to the invention, through a CRISPR / Cas9 technology, a codon CAC for coding 596th histidine in a No.14 exon of a mouse Zbtb20 gene is subjected to site-directed mutagenesis into CGC for coding arginine, and a hybrid mouse model for simulating pathogenic point mutation (p.H596R) of human Primrose syndrome is constructed. The model can stably reproduce key clinical phenotypes of the Primrose syndrome, including overgrowth after adult, serum IGF-1 rise, memory dysfunction and anxiety behaviors, and shows abnormal hippocampal neuronal development and synaptic transfer related pathways and the like. The invention provides an important experimental tool for deeply revealing the pathological mechanism of Primrose syndrome, developing drug screening and treatment intervention research and the like.

According to the application of the circular RNA circTrpc6 provided by the invention, experiments prove that the circTrpc6 is interfered, so that the cognitive function of SAMP8 can be improved, the hippocampal A beta expression and tau protein phosphorylation of SAMP8 mice can be obviously inhibited, the percentage of hippocampal neurons nissl bodies of the SAMP8 mice can be obviously reduced, and neuron damage can be alleviated; the number of hippocampal neuron branches, dendritic spine density and branch length of SAMP8 mice are obviously increased, and the shape plasticity of hippocampal synapses is improved. The results show that the circTrpc6 has potential treatment and prevention effects on tauopathy, dementia, AD (Alzheimer's disease) or other neurodegenerative diseases. Therefore, the circular RNA circTrpc6 can be used as a target spot for preparing the medicine for treating or preventing the neurodegenerative diseases.

The invention discloses a compound with remarkable 5-hydroxytryptamine (5-HT) reuptake inhibition activity, a preparation method of the compound and application of the compound in preparation of anti-depression drugs. And the compound is a compound Oreonudine C. The invention further discloses a preparation method of the compound. The preparation method of the Oreonudine C comprises the following steps: extracting with 95% ethanol, acidifying the extract, extracting with petroleum ether, adjusting the acid water layer to be alkaline with alkali liquor, extracting with chloroform, and performing silica gel column chromatography, C18 ODS column chromatography and preparative high performance liquid chromatography on the chloroform extraction part to obtain the Oreonudine C. The invention further discloses a preparation method of the Oreonudine C. The preparation method of the Oreonudine C comprises the following steps: extracting with 95% ethanol, acidifying the extract, extracting with petroleum ether, adjusting the acid water layer to be alkaline with alkali liquor, and obtaining the Oreonudine C. In-vitro experiments show that the compound Oreonudine C remarkably inhibits reabsorption of 5-HT (the inhibition rate is 60.4%) in mouse hippocampal neuronal cells HT22, and the inhibition rate of the compound Oreonudine C is superior to that of a positive control drug amitriptyline (the inhibition rate is 53.6%). The invention provides an important candidate compound for developing efficient and novel antidepressant drugs.

The application discloses expression regulation of alpha-synuclein and application thereof. The alpha-synuclein inhibitor is used for preparing a medicine, and the obtained medicine has the effects of preventing and treating anxiety caused by social isolation. Experiments prove that after the alpha-synuclein inhibitor is administered, the anxiety behavior of a model animal in a social isolation environment can be improved, and the alpha-synuclein inhibitor has a treatment effect on anxiety caused by social isolation. The alpha-synuclein inhibitor is selected from the following: 1) an ASO targeting SNCA mRNA coding alpha-synuclein; 2) a small-molecule compound targeting SNCA mRNA coding alpha-synuclein; or 3) an AAV interfering with the expression level of alpha-synuclein in a ventral hippocampal neuron.

The invention discloses application of a miR-5588-3p inhibitor, and belongs to the technical field of biological medicines. Researches find that the expression of miR-5588-3p in the plasma of an epileptic is abnormally increased. The miR-5588-3p inhibitor is given 72 hours before the tree shrew epilepsy model is constructed, so that the attack level, the convulsion rate and the death rate of the epilepsy tree shrew can be effectively reduced, and the brain pathological injury of the epilepsy tree shrew can be relieved. The miR-5588-3p inhibitor disclosed by the invention is used for preparing a medicine for treating epilepsy, and the nucleotide sequence of the miR-5588-3p inhibitor is as follows: GCUGGCAUUAGUGGGACUU. According to the present invention, the convulsion rate and the death rate of the epilepsy tree shrew can be well reduced, the matrix incubation period and the convulsion incubation period of the epilepsy tree shrew can be effectively prolonged, the convulsion duration of the epilepsy tree shrew can be shortened, the attack level of the epilepsy tree shrew can be effectively reduced, and the miR-5588-3p inhibitor can significantly reduce the hippocampal neuron damage.

The invention relates to the technical field of biological medicines, and discloses application of a ZBP1 inhibitor in preparation of a medicine for treating cognitive impairment caused by plastics. Research finds that exposure of a specific dose of nano plastic can activate a ZBP1 signal channel in an organism and promote assembly of a pan-apoptosis small body compound, so that pan-apoptosis cascade reaction with pyroptosis, apoptosis and necrosis characteristics is triggered, and finally hippocampal neuron damage, dysfunction and learning and memory ability decline are caused. Further research shows that expression of key protein of pan-apoptosis can be remarkably inhibited through local injection of the ZBP1 inhibitor to the hippocampus, cognitive function impairment induced by nano-plastics is effectively improved, and the key effect of ZBP1 serving as a core factor in the regulation and control process is defined. Based on the discovery, the ZBP1 inhibitor can be used for preparing the medicine for treating the plastic pollution related cognitive impairment, and a brand new treatment strategy is provided for clinical intervention of the diseases.

The application discloses an IGFBP-2 derived polypeptide and application thereof in preparation of an antidepressant, and relates to the technical field of biological medicines. The amino acid sequence of the polypeptide is Pro-Lys-Lys-Leu-Arg-Pro, the N terminal of which is acetylated and the C terminal of which is amidated, and the amino acid sequence is shown as SEQ ID NO:1. The polypeptide has a small molecular weight, can easily penetrate the blood-brain barrier, and has good stability after terminal modification. Animal experiments prove that the polypeptide can significantly improve the depressive behavior of Shank3 gene knockout mice, including improving the spatial cognitive ability, enhancing the social interaction and curiosity, and relieving the anxiety behavior. Cell experiments prove that the polypeptide can significantly improve the viability of hippocampal neuron cells from Shank3 gene knockout mice, and up-regulate the expression level of synaptic plasticity related proteins GluA1 and SYN1. The polypeptide can be prepared by a chemical synthesis method, has low cost, and can be used for preparing a medicine for preventing or treating depression (especially depression related to Shank3 gene mutation).

The application discloses application of TESC as an Alzheimer's disease prevention and treatment target and relates to the field of biological medicines. A TESC overexpression (TESC-OE) hippocampal neuron cell line is constructed through lentivirus transfection, and the result shows that TESC-OE has the ability to resist A beta-induced neuron apoptosis and synapse damage. A TESC overexpression model in the hippocampus of a mouse is constructed through stereotactic injection of an adeno-associated virus, and the result shows that the hippocampal gray matter volume in the brain of the TESC-OE mouse is significantly larger than that of a wild type mouse. A beta stereotactic modeling is performed on the basis of TESC overexpression in the hippocampus, and the result shows that the TESC-OE mouse can significantly resist A beta-induced hippocampal atrophy, learning and memory dysfunction and impaired synaptic plasticity. Immunoblotting analysis reveals the molecular mechanism that TESC can increase the expression of anti-apoptotic genes in the hippocampus and reduce the expression of pro-apoptotic genes to exert a neuroprotective effect.

The application belongs to the technical field of medicine, and particularly relates to a muscone derivative, a preparation method and application thereof. The muscone derivative cyclopentadecanedione monoxime has obvious advantages over muscone and other derivatives in improving the MCAO rat mNSS score, microcirculation blood flow, reducing the cerebral infarction rate, the cortical and hippocampal neuron necrosis rate, and the brain water content, and increasing the SOD and CAT contents of the rat brain tissue which are abnormally reduced due to ischemia, and is a potential effective drug for cerebral ischemia-reperfusion injury.

The application relates to the technical field of medicines, in particular to application of glycyrrhiza chalcone A in preparation of medicines for treating depression. The application experiment shows that the glycyrrhiza chalcone A can significantly improve the CUMS-induced depression-like behavior of mice, reduce the hippocampal neuron damage, inhibit the neuroinflammatory reaction, and restore the 5-HT level, and the anti-depression mechanism may be closely related to multiple mechanisms such as down-regulation of MAPK / JNK path activity, inhibition of inflammatory factor expression and neurotransmitter regulation.

The invention discloses application of a rhizoma acori graminei extract in preparation of a medicine for inhibiting nerve cell iron deposition and ferroptosis. In vitro and in vivo levels, the invention reveals that ATR reduces iron deposition and inhibits hippocampal neuron ferroptosis by activating Nrf2 / GPX4 axis, finally improves the pharmacological mechanism of AD cognitive expression, and preliminarily characterizes the main active components of ATR. And a new strategy direction and a material basis are provided for AD treatment.

The present invention discloses the use of Xinshubao tablets in preparing a drug for preventing and / or treating senile dementia. The present invention uses an AD animal model experiment constructed with scopolamine to determine that Xinshubao tablets improve the spatial learning and memory function of senile dementia mice by improving cortical and hippocampal tissue pathological damage, hippocampal neuron ultrastructure damage, and the cholinergic nervous system in the brain, and improving the neurotrophic state and synaptic function in the brain. The application of Xinshubao tablets in preventing and treating senile dementia has broad application prospects.

The application relates to the technical field of medicines, and particularly discloses a polypeptide and application of the polypeptide in preparation of a medicine for ischemic stroke. The amino acid sequence of the polypeptide is as shown in SEQ ID NO. 1. The polypeptide can significantly improve the nerve function defect of a mouse transient middle cerebral artery occlusion / reperfusion (tMCAO / R) model in vivo, reduce the cerebral infarction volume, and reduce the whole-body oxidative stress level. In vitro, the polypeptide has a direct protective effect on HT22 cells of mouse hippocampal neurons and hCMEC / D3 cells of human brain microvascular endothelium induced by oxygen-glucose deprivation (OGD), can resist the damage of corticosterone and MPP + induced PC12 cells, and effectively inhibits the accumulation of reactive oxygen species (ROS) in cells. The results show that the polypeptide has a multi-target cell protection activity, can play an anti-ischemic stroke role from multiple dimensions such as reduction of infarction volume, inhibition of oxidative stress level, and protection of nerve vascular units.

The present application mainly relates to the separation and identification and application of active ingredients in traditional Chinese medicine, and specifically discloses a separation and purification of a steroidal saponin compound in Allii Macrostemonis Bulbus. According to the physical and chemical properties and high-resolution electrospray mass spectrometry (HR-ESI-MS), one-dimensional / two-dimensional nuclear magnetic resonance spectroscopy (1D- / 2D-NMR) and other spectral technologies, the structure of the compound is identified, the structure is analyzed and the molecular formula is determined, and finally named as Allii Macrostemonis Bulbus saponin U. The pharmacological activity of Allii Macrostemonis Bulbus saponin U is studied through in vitro cell experiments, and it is found that Allii Macrostemonis Bulbus saponin U significantly improves the cell viability of mouse hippocampal neurons after glutamate treatment, has good neuroprotective activity, and can be used for the preparation and application of anti-nerve injury drugs.

The present invention relates to a composition for enhancing memory and preventing, ameliorating or treating cognitive impairment, comprising, as an active ingredient, a complex of Atractylodes macrocephala and Rumex acetosa extracts. The complex of Atractylodes macrocephala and Rumex acetosa extracts not only promotes CREB phosphorylation in hippocampal neurons, but also has a cytoprotective effect in brain neuronal cell lines, affects synapse remodeling at neuronal terminals that occurs during long-term potentiation (LTP), thereby increasing protein expression levels of synaptic remodeling factors and neuroplastic factors, and has been confirmed to improve short-term / long-term memory ability in behavioral evaluation of animal models, and thus can be effectively used as a health functional food, a medicine, or a feed additive, for enhancing memory and preventing, ameliorating or treating cognitive impairment.

The invention provides a traditional Chinese medicine composition for treating Parkinson's depression and a preparation method and application thereof, and belongs to the technical field of traditional Chinese medicines. The traditional Chinese medicine composition is prepared from the following raw materials in parts by weight: 1-10 parts of radix acanthopanacis semticosi and 1-10 parts of bulbus lilii. The invention also provides a preparation method of the traditional Chinese medicine composition, which comprises the following steps: taking the acanthopanax and the lily, adding water to soak, heating, refluxing and extracting, and combining filtrate to obtain the traditional Chinese medicine composition. Animal experiments find that the acanthopanax-lily traditional Chinese medicine composition has a good treatment effect on Parkinson depression for the first time, and can remarkably improve dyskinesia and depression symptoms, regulate neurotransmitter disorder, relieve damage to nigra and hippocampal neurons and reduce the level of inflammatory factors in serum. After being taken for a long time, the traditional Chinese medicine composition disclosed by the invention can improve depression and life quality, slow down the progress of Parkinson disease and reduce the use of Parkinson drugs.

The present invention belongs to the field of traditional Chinese medicine, and in particular to a kind of antidepressant Chinese medicine composition and its preparation method and application. The Chinese medicine composition of the present invention comprises, by weight, 55-65 parts of aconite, 55-65 parts of dried ginger, 85-95 parts of liquorice, 85-95 parts of cinnamon twig, 85-95 parts of white peony root, 290-310 parts of oyster, 85-95 parts of cornus, 40-55 parts of black plum, 145-155 parts of poria, 145-155 parts of spiny jujube seeds, 85-95 parts of jujube, 145-155 parts of yam, 55-65 parts of Morinda officinalis, 85-95 parts of ophiopogon, 25-35 parts of Amomum villosum, 25-35 parts of agarwood, 25-35 parts of cinnamon bark, 115-125 parts of polygonatum, 10-20 parts of tortoise shell glue, 10-20 parts of donkey-hide glue, and 10-20 parts of antler glue. Animal experiments show that the Chinese medicine composition of the present invention can effectively improve the behavioral manifestations of rats and mice with depression, reduce Nissl body damage in brain tissue, regulate the expression of p-TrkB / TrkB, p-AKT / AKT and p-CREB / CREB proteins in the hippocampus of brain tissue, and prevent and treat depression by improving the plasticity of hippocampal neurons.

The invention relates to the technical field of bioactive peptides, in particular to application of sipunculus nudus polypeptide in preparation of a neuroprotective drug. According to the specific technical scheme, firstly, sipunculus nudus oligopeptide is obtained through enzymolysis and an ultrafiltration membrane separation technology, the sipunculus nudus oligopeptide is separated and purified through sephadex chromatography, and on the basis of a high-glucose-induced mouse hippocampal neuron HT22 cell damage model, the collected components are separated and purified to obtain the sipunculus nudus oligopeptide. The neuroprotective effects of the sipunculus nudus oligopeptide and the separated components thereof are deeply discussed, and then the components in the sipunculus nudus oligopeptide are further separated and purified and subjected to mass spectrum peptide sequence identification by adopting reverse-phase high performance liquid chromatography. Experimental results show that the three components separated from the sipunculus nudus oligopeptide through sephadex chromatography can effectively improve the cell activity of HT22 cells after high glucose damage, and accumulation of ROS (reactive oxygen species) in the cells and occurrence of apoptosis are remarkably reduced.

The invention relates to the technical field of medicines, in particular to an iridium-kaempferol complex as well as a preparation method and application thereof. One Ir (Cp *) Cl2 structure in [Ir (Cp *) Cl2] 2 is substituted by one C15H10O6 to prepare the iridium-kaempferol complex, an Ir (III) center is combined with a kaempferol ligand for the first time, the metal organic complex Ir-Kae which not only utilizes the stability of the Ir (III) complex but also utilizes the pharmacological activity of kaempferol is developed, and through the synergistic effect of multiple mechanisms such as oxidation resistance, inflammation resistance and neuroprotection, the metal organic complex Ir-Kae can be used for preparing the metal organic complex. The spinal cord injury can be effectively treated at multiple target points. The Ir-Kae has a remarkable free radical scavenging capability, can effectively reduce the level of active oxygen in cells and organisms, realizes remarkable oxidation resistance and oxidative stress resistance, can improve the living and death degree of damaged hippocampal neurons, promotes neuronal repair, and has a remarkable anti-aging effect on hippocampal neurons. The nerve injury and the spinal cord injury are effectively treated, and a new direction is provided for assistant treatment of the spinal cord injury medicine.

The invention provides a new application of L-theanine in improvement of acute plateau hypoxia tolerance (viability), and finds and verifies that L-theanine can significantly improve the survival rate of mice in an acute hypobaric hypoxia environment and also can relieve brain tissue injury and body oxidative stress injury induced by plateau hypobaric hypoxia for the first time. And the generation of brain energy is promoted. In addition, in an in-vitro cell model, the L-theanine can also effectively improve hypoxia injury of the cobalt chloride induced hippocampal neuron cell line HT22. The invention provides a natural and safe active substance capable of improving the plateau hypoxia tolerance of an organism, provides a scientific basis for research and development of a series of acute physiological and pathological reactions caused by plateau hypoxia, and has a significant application value.

Here, the Inventors show that chronic IL- 1 -induced H2A.X signaling, which mediated DNA DSB response, in hippocampal neurons is a critical driver of cognitive deficits in chronic low grade neuroinflammation. They show that mice chronically infected with the brain- persisting T. gondii parasite display deficits in spatial memory consolidation without general memory loss. Extensive mapping of the neuroinflammatory landscape, beyond a latent T. gondii infection elicited type 1-like neuroinflammation, display elevated production of IL-1α and IL-1β in the hippocampus. Using a mouse model to specifically delete the IL-1 receptor from excitatory neurons, they uncovered that neuronal IL-1 signaling is required for the spatial memory deficits caused by latent T. gondii infection. By singling out a chronic exposure to IL- ip they found that IL-1β signaling in neurons indeed impairs spatial memory. Moreover, they showed that chronic exposure to IL-1β increases DNA DSB levels in neurons, and that neuronal H2A.X-dependent DSB response mediates the IL-1β-induced memory deficits. Importantly, neuronal DSBs were also increased upon T. gondii infection and the deficit in hippocampus- dependent spatial memory caused by T. gondii infection was prevented by the abrogation of neuronal H2A.Xdependent signaling. These results highlight the instrumental role of cytokine- induced DSB-dependent signaling in spatial memory defects elicited by a chronic infectious neuroinflammatory process. Accordingly, the present invention relates to a method of treating a subject suffering from cognitive deficit comprising administering to said subject a therapeutically effective amount of an inhibitor of IL- 1 -induced H2A.X signaling.

The invention provides a recombinant vector for regulating expression of a target gene by a promoter, and a construction method and application of the recombinant vector. The recombinant vector comprises a promoter and tag protein, the promoter is one of an hsyn promoter, a CMV promoter, a 1.2 kb NSE promoter and a CaMKII alpha promoter, and the tag protein is a Myc tag. According to the present invention, the recombinant vector containing the hsyn promoter, the CMV promoter, the 1.2 kb NSE promoter and the CaMKII alpha promoter can successfully drive the stable expression of the target gene (Prickle1 gene or Prickle2 gene) in the hippocampal neuron so as to provide the positive significance for the exploration of the effect of the Prickle protein in the neuron function.

The invention discloses application of indolepropionic acid or pharmaceutical salt thereof in preparation of a medicine for preventing and / or treating depression. The indole-3-propionic acid provided by the invention is used as an auxiliary medicine for treating depression, and the indole-3-propionic acid can relieve depression-like behaviors of depression mice and improve hippocampal neuron damage of the depression mice, so that the indole-3-propionic acid can be used as a medicine for treating depression.

The invention provides application of a probiotic-fructo-oligosaccharide-lycium ruthenicum microecological preparation for targeted hippocampal neuron repair in neuroprotection and a composite product, and relates to the technical field of microorganisms. The probiotic oligosaccharide composition provided by the invention comprises lycium ruthenicum powder, fructo-oligosaccharide and compound probiotic powder, the compound probiotic powder comprises plant lactobacillus, lactobacillus rhamnosus and bifidobacterium animalis subsp. Lactis, and the probiotic composition provided by the invention can significantly improve the neuron morphology and arrangement of a hippocampus area of a model group; the neuron damage is reduced.

The present invention belongs to the field of traditional Chinese medicine technology, specifically relating to a traditional Chinese medicine composition for improving cognitive impairment in coronary heart disease and its use. The raw materials of the composition include the following components: Alpinia oxyphylla, Lycium barbarum, Fructus schizonepetae, Lotus seed core, Panax ginseng, Ligusticum chuanxiong, and Paeonia lactiflora. The composition of the present invention can improve cardiac function and structure after acute myocardial ischemia in coronary heart disease, reduce the area of ​​ischemic myocardial infarction, alleviate myocardial cell damage and myocardial fibrosis, alleviate damage to hippocampal neurons and ultrastructural changes, and improve learning and memory functions and cognitive behavioral performance.

The present invention relates to the field of treat age-related cognitive declines. In this study, the inventors report that GPR158, which localizes at the PC, is required for OCN- dependent autophagy induction in hippocampal neurons. Consistently, the mobilization of key autophagy players by OCN in hippocampal neurons requires core PC-proteins. In aged hippocampi, neuronal PC present an abnormal morphology, correlated with a reduction of the major core ciliary proteins levels. Conversely, restoration of their levels in aged hippocampi is sufficient to improve autophagy and cognitive deficits. Lastly, they show that core PC-proteins are required to integrate the rejuvenating effects of OCN in the hippocampus, thereby ameliorating age-related cognitive deficits. Altogether, these findings demonstrate a new paradigm for the neuron / systemic milieu communication and significantly advance our understanding of the regulatory mechanism mediating the rejuvenating effects of the pro-youth blood factor, OCN, in hippocampal neurons. This study also provides the foundation for novel therapeutic strategies to treat age-related cognitive decline, as well as neurological deficits in ciliopathies. Thus, the present invention relates to an activator of the primary cilia (PC) for use in the restoration and / or improvement of cognitive functions in a subject in need thereof.

The invention discloses an application of N-acetyl-5-hydroxytryptamine or a pharmaceutical salt thereof in preparation of a medicine for preventing and / or treating depression. The N-acetyl-5-hydroxytryptamine provided by the invention can relieve depression-like behaviors of depressive mice and improve hippocampal neuron damage of the depressive mice, so that the N-acetyl-5-hydroxytryptamine can be used as a medicine for preventing or treating depression.

The invention belongs to the technical field of chemistry, and particularly relates to an artificial synthesis method and application of a compound theanine diglucoside TFG. Theanine-fructosyl-glucose (TFG) is a Maillard reaction product, has obvious antioxidant activity, and is not systematically studied at present, so that the antioxidant activity of the theanine-fructosyl-glucose (TFG) can be obviously improved, and the antioxidant activity of the theanine-fructosyl-glucose (TFG) can be obviously improved. The invention provides an efficient artificial synthesis method of the compound TFG, the synthesis cost is reduced, a material basis is provided for subsequent research, and the method has the characteristics of economy, high efficiency, simplicity in operation, safety and the like, and is suitable for industrial production. Subsequently, activity screening of HT22 mouse hippocampal neuronal cells and HUVEC human vascular endothelial cells in vitro proves that the compound TFG can remarkably relieve cell oxidative damage induced by hydrogen peroxide (H2O2). Based on the synergistic protection effect of the TFG on neurons and vascular endothelial systems, the TFG is suitable for developing antioxidant drugs for treating Alzheimer's disease.